fashion -WSS

fashion

author：fashion 2025-09-30 02:09:32 - browse：59348

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Crowdfunding for medical bills sidesteps core problem, author says

entertainment

leisure time

WSS

Can gargling with Listerine treat gonorrhea of the mouth?

As health system earnings go up, health insurance stocks go down

As health system earnings go up, health insurance stocks go down

Schizophrenia gene found to be linked to cells' energy dysfunction

Brain MRIs reveal impact of 'toxic stress' on Black children

Lawmakers grill UnitedHealth CEO on Change cyberattack

knowledge

fashion

explore

The cancer drug shortage isn’t new — and neither are the solutions

Biden administration begins canceling student loan debt for 804,000 borrowers

Guidelines to prevent youth baseball injuries need more muscle

Is it ever OK for doctors to lie to their patients?

Wildfire smoke exposes gaps in outdoor worker protections

Welsh Carson private equity firm escapes from FTC antitrust case

Jerome Adams on the need for new antivirals for Covid

AltruBio raises $225 million to develop ulcerative colitis drug

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Indictment alleges Trump's ex

hotspot

AltruBio raises $225 million to develop ulcerative colitis drug

After Optum profits sink, UnitedHealth makes changes

Megan Rapinoe shares emotional post following US Women's World Cup exit

Biogen’s boardroom scandal saddles CEO with first crisis

Health AI: on the border between health care and tech

Judge sides with young activists in first

focus

entertainment

leisure time

explore